{
  "kind": "story",
  "slug": "508-robinhood-is-handing-customers-and-investors-a-gold-en-o-0016846",
  "id": 1779597538580016846,
  "record_id": 1779581788601522133,
  "headline": "#508: Robinhood Is Handing Customers And Investors A 'Gold'en Opportunity, & More",
  "summary": "",
  "source": "ark-invest-newsletters",
  "source_url": "https://ark-invest.com/newsletters/issue-508",
  "home_domain": "economics-business-work",
  "claim_type": null,
  "sentiment": "mixed",
  "significance": "high",
  "claim_count": 128,
  "reading_time_minutes": 9,
  "published_date": "2026-05-04",
  "created_on": "2026-05-24T04:38:58.235421+00:00",
  "claims": [
    {
      "id": 1779597539090369630,
      "text": "If approved, lonvo-z would be the world's first gene-editing therapy delivered in-vivo (inside the body).",
      "evidence_type": "direct_quote",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539614268410,
      "text": "AI is amplifying, not cannibalizing, the legacy cloud business.",
      "evidence_type": "direct_quote",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597538978341055,
      "text": "Robinhood Gold is designed to transform intermittent brokerage users into high-frequency financial users.",
      "evidence_type": "direct_quote",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539038770533,
      "text": "Robinhood is shifting from a transactional model to a recurring revenue, relationship-driven model.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539710983098,
      "text": "The hyperscalers' capital expenditure (capex) is racing to keep pace with contracted demand, not chasing a hypothetical future.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539574081909,
      "text": "Cloud growth is accelerating, not maturing, driven by strong AI adoption.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539786874958,
      "text": "Major equity index providers are overhauling their inclusion rules in anticipation of a potentially largest IPO wave in history.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539050958160,
      "text": "Gold subscriptions have been generating approximately $100 million in annualized recurring revenue (ARR).",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597538970320846,
      "text": "Robinhood Gold is following a playbook similar to Amazon Prime, priced to maximize adoption instead of near-term revenue.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597538958252410,
      "text": "Gold users adopt retirement accounts at 3.3-times the rate of non-Gold users.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539022106783,
      "text": "Robinhood's products are reinforcing one another: Banking drives deposits, deposits fund investing, and spending data informs credit.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539154432831,
      "text": "On average, HAE patients experience two or more attacks per month, each lasting several days if untreated.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539162106603,
      "text": "HAE patients on modern prophylactics face lifelong chronic treatment that does not fully protect against occasional attacks.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539054929635,
      "text": "The Gold Card is generating annualized recurring revenue not far behind Gold subscriptions.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539010431518,
      "text": "Robinhood Strategies hit $1.5 billion in assets under management (AUM) in little more than a year.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539006112093,
      "text": "The Gold Card has quadrupled to 765,000 users over the past year.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597538966541706,
      "text": "Approximately 40% of new Robinhood users opt into Gold at signup.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539257049966,
      "text": "During the six-month efficacy evaluation period, lonvo-z patients experienced 87% fewer attacks than placebo patients.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539110690535,
      "text": "Lonvo-z could pave the way for one-time treatments to reach a much broader range of diseases.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539114812796,
      "text": "HAE is a rare genetic disease impacting approximately 7,000 patients in the US.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539118343362,
      "text": "HAE patients are diagnosed at an average age of 20 years.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539126911469,
      "text": "HAE leads to the overproduction of bradykinin, an inflammatory molecule.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539130606413,
      "text": "Bradykinin triggers sudden, painful swelling attacks in the face, abdomen, extremities, and airway.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539138453241,
      "text": "HAE attacks can be life-threatening when they impact the throat.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539382065523,
      "text": "By the end of 2025, approximately 90% of eligible US Casgevy patients enjoyed reimbursed access.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539158370802,
      "text": "Modern prophylactic HAE therapies reduce attack rates by approximately 70-90% in Phase 3 trials.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539433885542,
      "text": "ARK's research estimates a real-world price of $3 million per HAE patient for lonvo-z.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539178908015,
      "text": "Casgevy was the first CRISPR-based gene-editing therapy to reach the market.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539186775823,
      "text": "Casgevy treats sickle cell disease.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539199070094,
      "text": "Casgevy uses ex-vivo gene editing, where cells are edited outside the body.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539082131140,
      "text": "The lonvo-z readout is a landmark for gene-editing.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539002062816,
      "text": "Robinhood Banking accumulated $1.6 billion in deposits in the first quarter, two quarters after rolling out.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539226625654,
      "text": "Inactivating KLKB1 interrupts the production of bradykinin, preventing HAE swelling attacks.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539218338950,
      "text": "Lonvo-z's editing tools inactivate KLKB1 in the liver, the gene that produces kallikrein.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539238130735,
      "text": "Patients receive the lonvo-z infusion in an outpatient setting over two to four hours.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539242329489,
      "text": "Intellia's Phase 3 trial randomly assigned 80 HAE patients in a 2:1 ratio to receive either lonvo-z or a placebo.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539078218606,
      "text": "Lonvo-z is a one-time gene-editing therapy for hereditary angioedema (HAE).",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539266573927,
      "text": "100% of lonvo-z patients benefited from some reduction in attack rate relative to baseline.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539271916215,
      "text": "62% of lonvo-z patients experienced no attacks at all.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539274211203,
      "text": "The lonvo-z trial results met its endpoints with high statistical significance.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539294878735,
      "text": "The trial used a crossover design, with placebo patients receiving lonvo-z after a six-month observation period.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539306292716,
      "text": "Mean attack rates in both the original treatment arm and the placebo crossover arm fell rapidly to nearly zero within 8 weeks of crossover dosing.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539310095923,
      "text": "Every patient who received lonvo-z benefited from the near-elimination of attacks.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539314702183,
      "text": "Lonvo-z had a favorable safety profile with no serious liver safety signals.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539322214481,
      "text": "One critique of lonvo-z is its permanence, questioning why to choose an irreversible gene edit over effective prophylactics.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539326510325,
      "text": "Intellia's survey data show 68% of HAE patients are highly concerned about the need for lifetime medication.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539342764720,
      "text": "Intellia's survey data show 80% of HAE patients are concerned about shifts in health insurance coverage inhibiting therapy access.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539366208493,
      "text": "A one-time treatment like lonvo-z would eliminate concerns about lifetime medication and insurance coverage shifts.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539373789742,
      "text": "A second critique suggests the lonvo-z edit might not be permanent enough due to limited long-term durability data.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539381721539,
      "text": "Critiques about permanence and durability echoed those Casgevy navigated after its approval.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539214157028,
      "text": "Lonvo-z uses in-vivo gene editing, where editing components are delivered through one intravenous infusion.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539390663448,
      "text": "The number of patients receiving Casgevy infusions jumped from 5 in 2024 to 64 during 2025.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539406332109,
      "text": "The US wholesale acquisition cost for Casgevy is $2.2 million per dose.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539423465270,
      "text": "Commercial uptake for gene-editing therapies is accelerating even at premium pricing.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539210541126,
      "text": "The Casgevy treatment journey can take up to 12 months to complete, involving stem-cell collection, chemotherapy, infusion, and recovery.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539438369653,
      "text": "ARK's modeled value-based price for lonvo-z is approximately $11 million per HAE patient.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539443463274,
      "text": "A one-time gene-editing therapy for every HAE patient today could save the healthcare system approximately $52 billion in direct costs over the remaining lives of the ~7,000 US patients.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539456748079,
      "text": "Cost savings create a clear incentive for payers to reimburse a one-time treatment over costly lifelong prophylactic care.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539461810346,
      "text": "The Institute for Clinical and Economic Review (ICER) concluded that lifelong prophylactic HAE care is priced above the value delivered.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    },
    {
      "id": 1779597539070783720,
      "text": "Intellia Therapeutics reported positive topline Phase 3 results for lonvoguran ziclumeran (lonvo-z) last week.",
      "evidence_type": "paraphrase",
      "confidence": "stated",
      "home_domain": "economics-business-work",
      "published_date": "2026-05-04"
    }
  ],
  "tags": [
    {
      "id": 17723038993598633,
      "slug": "alphabet-organization",
      "name": "Alphabet",
      "type": "organization"
    },
    {
      "id": 17723038993598907,
      "slug": "amazon-organization",
      "name": "Amazon",
      "type": "organization"
    },
    {
      "id": 17723038993599352,
      "slug": "anthropic-organization",
      "name": "Anthropic",
      "type": "organization"
    },
    {
      "id": 17723038993786763,
      "slug": "ark-investment-management-llc-organization",
      "name": "ARK Investment Management LLC",
      "type": "organization"
    },
    {
      "id": 17733540814965381,
      "slug": "crispr-therapeutics-organization",
      "name": "CRISPR Therapeutics",
      "type": "organization"
    },
    {
      "id": 17730927281170820,
      "slug": "food-and-drug-administration-organization",
      "name": "Food and Drug Administration",
      "type": "organization"
    },
    {
      "id": 17723038994579919,
      "slug": "ftse-russell-organization",
      "name": "FTSE Russell",
      "type": "organization"
    },
    {
      "id": 17733517869622281,
      "slug": "google-organization",
      "name": "Google",
      "type": "organization"
    },
    {
      "id": 17731272121204945,
      "slug": "intellia-therapeutics-organization",
      "name": "Intellia Therapeutics",
      "type": "organization"
    },
    {
      "id": 17723038993598722,
      "slug": "microsoft-organization",
      "name": "Microsoft",
      "type": "organization"
    },
    {
      "id": 17733516549329087,
      "slug": "morningstar-organization",
      "name": "Morningstar",
      "type": "organization"
    },
    {
      "id": 17723038993603884,
      "slug": "nasdaq-organization",
      "name": "Nasdaq",
      "type": "organization"
    },
    {
      "id": 17723038993599257,
      "slug": "openai-organization",
      "name": "OpenAI",
      "type": "organization"
    },
    {
      "id": 17733540881561958,
      "slug": "rev-organization",
      "name": "Rev",
      "type": "organization"
    },
    {
      "id": 17726658249148074,
      "slug": "robinhood-organization",
      "name": "Robinhood",
      "type": "organization"
    },
    {
      "id": 17723038993600329,
      "slug": "spacex-organization",
      "name": "SpaceX",
      "type": "organization"
    },
    {
      "id": 17724164495443627,
      "slug": "s-p-dow-jones-indices-llc-organization",
      "name": "S&P Dow Jones Indices LLC",
      "type": "organization"
    },
    {
      "id": 17723038993599170,
      "slug": "tesla-organization",
      "name": "Tesla",
      "type": "organization"
    },
    {
      "id": 17733540814951122,
      "slug": "vertex-pharmaceuticals-organization",
      "name": "Vertex Pharmaceuticals",
      "type": "organization"
    },
    {
      "id": 17724158118284112,
      "slug": "jozef-soja-person",
      "name": "Jozef Soja",
      "type": "person"
    },
    {
      "id": 17724158133646124,
      "slug": "nicholas-grous-person",
      "name": "Nicholas Grous",
      "type": "person"
    },
    {
      "id": 17724158118440419,
      "slug": "shea-wihlborg-person",
      "name": "Shea Wihlborg",
      "type": "person"
    },
    {
      "id": 17726698827490737,
      "slug": "tasha-keeney-person",
      "name": "Tasha Keeney",
      "type": "person"
    },
    {
      "id": 17724158130441674,
      "slug": "varshika-prasanna-person",
      "name": "Varshika Prasanna",
      "type": "person"
    },
    {
      "id": 17723038993608963,
      "slug": "united-states-place",
      "name": "United States",
      "type": "place"
    },
    {
      "id": 17723038993834764,
      "slug": "artificial-intelligence-topic",
      "name": "Artificial Intelligence",
      "type": "topic"
    },
    {
      "id": 17723038993835295,
      "slug": "cloud-computing-topic",
      "name": "Cloud Computing",
      "type": "topic"
    },
    {
      "id": 17723038993836449,
      "slug": "equity-markets-topic",
      "name": "Equity Markets",
      "type": "topic"
    },
    {
      "id": 17730927060144832,
      "slug": "gene-therapy-topic",
      "name": "Gene Therapy",
      "type": "topic"
    },
    {
      "id": 17723038993837696,
      "slug": "ipo-market-topic",
      "name": "IPO Market",
      "type": "topic"
    }
  ]
}